Deltex Medical Regulatory News (DEMG)

12 May 2016

Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")

Two additional US accounts added to platform programme

Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), is pleased to announce that it has added two additional hospital accounts to its platform programme in the USA.

The first account is a sister hospital of one of our longest established platform accounts. Deltex responded to increased interest from the additional account in 2015 by allocating clinical support within its dedicated trainer programme. Since then, probe sales have grown steadily and are now running at over 50 probes a month. This account becomes the fifth platform account in the Company's West Coast territory.

The second account comprises two linked facilities in Oklahoma and is the second remote trainer platform account, which the Company is supporting out of its Mid-West territory, with occasional on-site training to supplement the Company's e-learning programmes. The account is the fourth platform account in the territory and is currently using around 35 to 40 probes a month which it expects to increase as it expands its adoption of enhanced recovery surgical programmes.

These are Deltex's fourth and fifth new platform programme accounts in 2016 bringing the total number of US platform accounts to 22. This further illustrates the success of the Company's ongoing strategy to focus on the USA as its key market.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"The USA is our key territory of focus and adoption rates continue to outperform our other areas of development. Each additional platform account adds incremental momentum to our US business, where probe revenues in the year to date are running over 50% ahead of the corresponding period in 2015. We remain on track to achieve our target of opening 30 US hospital platform accounts in the middle part of the year."

For further information, please contact:-

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and over 650,000 patients have been treated to date using Deltex Medical's single patient disposable probes.